GB2292145A — Pyrrolo-pyridine derivatives

USPTO Abstract

Compounds of formula: <IMAGE> wherein the broken line represents an optional chemical bond; A represents hydrogen, C1-6 alkyl, C1-6 alkoxy, halogen, cyano or trifluoromethyl; R represents hydrogen or C1-6 alkyl; R<1> represents a halogen atom; R<2> represents an optionally substituted C1-6 alkyl, C1-6 alkoxy, C2-6 alkenyl, C2-6 alkynyl, aryl, aryl(C1-6)alkyl, aryloxy(C1-6)alkyl, aryl(C1-6)alkoxy, aryl(C2-6)alkenyl, aryl(C2-6)alkynyl, C3-7 heterocycloalkyl (C1-6)alkyl, heteroaryl, heteroaryl(C1-6)alkyl, heteroaryl(C2-6)alkenyl or heteroaryl(C2-6)alkynyl group; R<3>, R<4> and R<5> independently represent hydrogen, hydrocarbon, a heterocyclic group, halogen, cyano, trifluoromethyl, nitro, -OR<a>, -SR<a>, -SOR<a>, -SO2R<a>, -SO2NR<a>R<b>, NR<a>R<b>, -NR<a>COR<b>, -NR<a>CO2R<b>, -COR<a>, -CO2R<a> or -CONR<a>R<b>; and R<a> and R<b> independently represent hydrogen, hydrocarbon or a heterocyclic group, and salts and prodrugs thereof are useful in the treatment or prevention of disorders of the dopamine system, in particular schizophrenia.